Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00009204 |
This study is a randomized, double-blind, placebo-controlled, fixed dose study currently being conducted on two geropsychiatric units at Western Psychiatric Institute and Clinic. It seeks to evaluate the short-term safety and efficacy of citalopram and perphenazine in the treatment of 112 patients suffering from behavioral disturbances associated with dementia. Findings from this research may directly lead to improved acute pharmacotherapy for psychosis and behavioral problems in patients diagnosed with dementia. Improved treatment of behavioral complications with reduced side effects would reduce excess disability in patients diagnosed with dementia, allowing them to be maintained in the community for greater periods of time.
Condition | Intervention | Phase |
---|---|---|
Dementia Alzheimer Disease Dementia, Vascular |
Drug: Citalopram [Celexa] Drug: Perphenazine [Trilafon] |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control |
Official Title: | Serotonergic Pharmacotherapy for Agitation of Dementia |
The principal investigator is conducting an inpatient study at Western Psychiatric Institute and Clinic involving two medications for treatment of emotional and behavioral disturbances that may accompany dementia. In this study, 112 patients will be enrolled for up to 17 days in order to investigate the safety and effectiveness of both medications. Forty-two of these patients will be given a recently FDA-approved antidepressant medication called citalopram and 42 will receive one of our current, usual antipsychotic medications called perphenazine. An additional 28 patients will be given non-active placebo capsules. Which treatment a patient is given during the study will be determined by chance. Findings from this investigation may directly lead to the improvement of symptoms such as: agitation, hostility, suspiciousness, hallucinations, and unusual thoughts. Improved treatment of problematic behaviors and a decrease in medication-associated side effects would enable dementia patients to be cared for in their home environments for longer periods of time.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Pennsylvania | |
University of Pittsburgh Western Psychiatric Institute and Clinic | |
Pittsburgh, Pennsylvania, United States, 15213 |
Principal Investigator: | Bruce G. Pollock, M.D., Ph.D. | Western Psychiatric Institute and Clinic |
Study ID Numbers: | R01 MH59666-01, IA0014, DSIR GT-GP |
Study First Received: | January 23, 2001 |
Last Updated: | November 18, 2005 |
ClinicalTrials.gov Identifier: | NCT00009204 |
Health Authority: | United States: Federal Government |
Behavioral problems Agitation |
Arterial Occlusive Diseases Alzheimer Disease Vascular Diseases Central Nervous System Diseases Psychomotor Agitation Arteriosclerosis Brain Diseases Neurodegenerative Diseases Citalopram Intracranial Arterial Diseases Cerebrovascular Disorders |
Cognition Disorders Intracranial Arteriosclerosis Dopamine Delirium, Dementia, Amnestic, Cognitive Disorders Perphenazine Mental Disorders Dementia, Vascular Dexetimide Dementia Delirium |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Dopamine Antagonists |
Antipsychotic Agents Pharmacologic Actions Therapeutic Uses Cardiovascular Diseases Dopamine Agents Tauopathies Central Nervous System Agents |